Takeda, Cell Genesys Halt Phase III Trial Of Cancer Vaccine
This article was originally published in PharmAsia News
Executive Summary
U.S.-based Cell Genesys and Japanese partner Takeda Pharmaceutical have stopped a Phase III trial of GVAX, a vaccine they co-developed to prevent prostate cancer. Cell Genesys acted after deaths of trial participants given GVAX exceeded by 20 the number of those on a placebo. The company said it had not identified the cause of the deaths. A spokesman said the firm was reviewing the matter with Takeda and considering a possible change in the business operations between the two partners. (Click here for more